{
    "Symbol": "BMRN",
    "AssetType": "Common Stock",
    "Name": "Biomarin Pharmaceutical Inc",
    "Description": "BioMarin Pharmaceutical Inc. develops and markets therapies for people with rare diseases and serious and life-threatening medical conditions. The company is headquartered in San Rafael, California.",
    "CIK": "1048477",
    "Exchange": "NASDAQ",
    "Currency": "USD",
    "Country": "USA",
    "Sector": "LIFE SCIENCES",
    "Industry": "PHARMACEUTICAL PREPARATIONS",
    "Address": "105 DIGITAL DRIVE, NOVATO, CA, US",
    "FiscalYearEnd": "December",
    "LatestQuarter": "2024-03-31",
    "MarketCapitalization": "16067646000",
    "EBITDA": "293470000",
    "PERatio": "79.83",
    "PEGRatio": "0.76",
    "BookValue": "26.74",
    "DividendPerShare": "None",
    "DividendYield": "None",
    "EPS": "1.06",
    "RevenuePerShareTTM": "13.12",
    "ProfitMargin": "0.0831",
    "OperatingMarginTTM": "0.121",
    "ReturnOnAssetsTTM": "0.0177",
    "ReturnOnEquityTTM": "0.0422",
    "RevenueTTM": "2471644000",
    "GrossProfitTTM": "1612370000",
    "DilutedEPSTTM": "1.06",
    "QuarterlyEarningsGrowthYOY": "0.722",
    "QuarterlyRevenueGrowthYOY": "0.088",
    "AnalystTargetPrice": "108.23",
    "AnalystRatingStrongBuy": "6",
    "AnalystRatingBuy": "14",
    "AnalystRatingHold": "8",
    "AnalystRatingSell": "0",
    "AnalystRatingStrongSell": "0",
    "TrailingPE": "79.83",
    "ForwardPE": "34.36",
    "PriceToSalesRatioTTM": "7.23",
    "PriceToBookRatio": "3.536",
    "EVToRevenue": "7.25",
    "EVToEBITDA": "56.6",
    "Beta": "0.319",
    "52WeekHigh": "99.56",
    "52WeekLow": "73.67",
    "50DayMovingAverage": "82.14",
    "200DayMovingAverage": "86.68",
    "SharesOutstanding": "189880000",
    "DividendDate": "None",
    "ExDividendDate": "None"
}